Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2223449/ultragenyx-rare-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223449
Feb 08, 2024 - Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2226283
Feb 14, 2024 - Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
0
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2227145/ultragenyx-rare-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227145
Feb 15, 2024 - Ultragenyx (RARE) delivered earnings and revenue surprises of 7.88% and 4.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
https://www.zacks.com/stock/news/2227212/compared-to-estimates-ultragenyx-rare-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2227212
Feb 15, 2024 - Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
0
Ramstad: A rare moment of political practicality — and agreement — at Minnesota Chamber
https://www.startribune.com/ramstad-a-rare-moment-of-political-practicality-and-agreement-at-minnesota-chamber/600344253/
Feb 17, 2024 - The national immigration debate is a mess, but Minnesota's legislative leaders understand its complexity and economic importance.
0
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
https://seekingalpha.com/article/4675691-rare-stock-picks-in-february-2024-from-32-discerning-analysts?source=feed
Mar 05, 2024 - In our monthly Rare Stock Picks series, we're highlighting February 2024 investment picks. Click here for the list of February 2024 Buy recommendations.
0
StoneCo: A Very Rare Find At This Price
https://seekingalpha.com/article/4677227-stoneco-stne-stock-a-very-rare-find-at-this-price?source=feed
Mar 10, 2024 - StoneCo has shown strong revenue growth and improving financial results. Check out why we rate STNE stock as a strong buy.
0
Citi starts Catalyst at buy, cites rare disease drug portfolio
https://seekingalpha.com/news/4079636-citi-starts-catalyst-at-buy-cites-rare-disease-drug-portfolio?source=feed_sector_healthcare
Mar 14, 2024 - Citi started coverage of Catalyst Pharmaceuticals (CPRX) with a buy rating, citing the company’s rare disease drug portfolio that it views as largely de-risked. Read more here.
0
Lisata gets FDA rare pediatric disease status for lead drug
https://seekingalpha.com/news/4082189-lisata-gets-fda-rare-pediatric-disease-status-for-lead-drug?source=feed_sector_healthcare
Mar 21, 2024 - Lisata Therapeutics (LSTA) said its lead drug candidate LSTA1 has received Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma. Read more here.
0
Page 1>